Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026)

Cogent Biosciences' Total Current Liabilities history spans 10 years, with the latest figure at $58.0 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 17.57% to $58.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $58.0 million through Mar 2026, up 17.57% year-over-year, with the annual reading at $64.0 million for FY2025, 14.8% up from the prior year.
  • Total Current Liabilities came in at $58.0 million for Q1 2026, down from $64.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $64.0 million in Q4 2025 to a low of $17.9 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $38.2 million (2023), against an average of $40.8 million.
  • Year-over-year, Total Current Liabilities surged 116.93% in 2022 and then decreased 6.87% in 2023.
  • Cogent Biosciences' Total Current Liabilities stood at $26.8 million in 2022, then surged by 42.16% to $38.2 million in 2023, then skyrocketed by 45.96% to $55.7 million in 2024, then rose by 14.8% to $64.0 million in 2025, then fell by 9.34% to $58.0 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Total Current Liabilities are $58.0 million (Q1 2026), $64.0 million (Q4 2025), and $62.2 million (Q3 2025).